Why the study?
Does nightly nasal continuous positive airway pressure improve left ventricular ejection fraction in patients with congestive heart failure and Cheyne-Stokes respiration with central sleep apnea?
Does nightly nasal continuous positive airway pressure improve left ventricular ejection fraction in patients with congestive heart failure and Cheyne-Stokes respiration with central sleep apnea?
Nightly NCPAP improves left ventricular ejection fraction, attenuates sleep apnea, and alleviates symptoms in patients with heart failure and Cheyne-Stokes respiration.
Answers are grounded in this paper and cite their sources.
NCPAP may improve LVEF in HF with Cheyne-Stokes respiration and central sleep apnea; extends RCT evidence for treating sleep-disordered breathing in this population.
A previous uncontrolled study suggested that nasal continuous positive airway positive airway pressure (NCPAP) may improve left ventricular ejection fraction (LVEF) in patients with congestive heart failure (CHF) and Cheyne-Stokes respiration with central sleep apnea (CSR-CSA). In order to more critically evaluate the effects of NCPAP on cardiac function, we undertook a randomized, controlled trial of NCPAP in 29 patients with heart failure and CSR-CSA over a 3-mo period, with LVEF as the primary outcome measure. Patients with CHF and associated CSR-CSA who were receiving optimal medical therapy were randomly assigned to a control group (n = 15) or a group receiving nightly NCPAP (n = 14). Twelve patients in each group completed the study. There was a greater improvement of LVEF in the NCPAP group than in the control group during the study (mean +/- SEM = 7.7 +/- 2.5 versus - 0.5 +/- 1.5%, p = 0.019). In addition, there was a significantly greater reduction in the number of apneas and hypopneas (-28.5 +/- 3.9 versus -6.1 +/- 7.0 per hour of sleep, p = 0.012) in the NCPAP group than in the control group. Significantly greater improvements in symptoms of fatigue (5.6 +/- 1.2 versus 0.8 +/- 0.7, p = 0.005) and disease mastery (3.6 +/- 1.1 versus -0.7 +/- 0.7, p = 0.031) were also observed in the NCPAP group. We conclude that in patients with chronic heart failure and CSR-CSA, nightly administration of NCPAP can attenuate CSR-CSA, improve cardiac function, and alleviate symptoms of heart failure.
No takes yet. Share an insight, caveat, or question.
Naughton et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: